MAPT and tauopathy: It was demonstrated that both intracerebroventricular infusion and peripheral administration of antibodies specific to Tau25–30 are therapeutic in P301S mouse model of tauopathy [43, 72], although very high concentration (50 mg/kg) of systemically administered (i.p.)antibodies are needed to achieve significant decrease in insoluble tau, prevent brain atrophy, and see improvement of motor/sensorimotor function [72].